CLVS.F Stock Overview

Develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. More details

CLVS.F fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	5/6
Past Performance	3/6
Financial Health	6/6
Dividends	3/6

Rewards

Trading at 13.6% below our estimate of its fair value

Earnings are forecast to grow 20.7% per year

Earnings have grown 9% per year over the past 5 years

Analysts in good agreement that stock price will rise by 20.3%

Risk Analysis

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

CellaVision AB (publ) Competitors

Semler Scientific

NasdaqCM:SMLR

US$456.0m

Tactile Systems Technology

NasdaqGM:TCMD

US$410.1m

Electromed

NYSEAM:ELMD

US$279.5m

Zynex

NasdaqGS:ZYXI

US$243.9m

Price History & Performance

Summary of share price highs, lows and changes for CellaVision
Historical stock prices
Current Share Price	SEK 19.28
52 Week High	SEK 25.91
52 Week Low	SEK 19.28
Beta	1.23
1 Month Change	-3.17%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	959.32%

Recent updates

Shareholder Returns

	CLVS.F	US Medical Equipment	US Market
7D	0%	0.4%	1.2%
1Y	n/a	13.3%	21.0%

Return vs Industry: Insufficient data to determine how CLVS.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how CLVS.F performed against the US Market.

Price Volatility

Is CLVS.F's price volatile compared to industry and market?
CLVS.F volatility
CLVS.F Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	8.1%
Market Average Movement	6.0%
10% most volatile stocks in US Market	18.5%
10% least volatile stocks in US Market	3.0%

Stable Share Price: CLVS.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine CLVS.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1994	228	Simon Ostergaard	www.cellavision.com

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides CellaVision DM1200 and CellaVision DM9600, designs to automate and simplify the process of performing blood and body fluid differentials; CellaVision DC-1, an analyzer to enable low-volume hematology labs to implement CellaVisions digital methodology for performing blood cell; and DIFF-Line that automates and digitizes the process of analyzing peripheral blood smears. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process.

CellaVision AB (publ) Fundamentals Summary

How do CellaVision's earnings and revenue compare to its market cap?
CLVS.F fundamental statistics
Market cap	US$439.77m
Earnings (TTM)	US$12.88m
Revenue (TTM)	US$66.18m

34.2x

P/E Ratio

6.6x

P/S Ratio

Is CLVS.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CLVS.F income statement (TTM)
Revenue	SEK 723.22m
Cost of Revenue	SEK 236.14m
Gross Profit	SEK 487.07m
Other Expenses	SEK 346.35m
Earnings	SEK 140.72m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Apr 29, 2025

Earnings per share (EPS)	5.90
Gross Margin	67.35%
Net Profit Margin	19.46%
Debt/Equity Ratio	3.3%

How did CLVS.F perform over the long term?

See historical performance and comparison

Dividends

1.2%

Current Dividend Yield

42%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/11 13:14
End of Day Share Price	2025/01/23 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CellaVision AB (publ) is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Sten Gustafsson	ABG Sundal Collier
Bjorn Rydell	ABG Sundal Collier Sponsored
Carl-Oscar Bredengen	Berenberg